Regentis Biomaterials (RGNT)
Develops a cell-free hydrogel implant for focal knee-cartilage repair.
Something off on this page? Send us feedback.
Develops GelrinC, a cell-free hydrogel implant for focal knee-cartilage injuries, delivered as a liquid and cured in place with ultraviolet light. A pre-revenue, single-platform developer, it relies on clinical progress, regulatory approval, contract manufacturing and commercial partners.
Develops GelrinC, a cell-free, ready-to-use hydrogel for focal knee-cartilage injuries. Delivered as a liquid, it fills a cartilage defect and is cured with ultraviolet light into an implant that erodes as new tissue fills the space. GelrinC is CE-marked in Europe, while its United States program remains investigational and is centered on a pivotal study supporting a PMA submission.
Operates from Israel with a lean, outsourced model: contract manufacturers produce trial batches, while clinical, quality and specialist work relies on contractors. Planned commercialization in Europe and the United States depends on strategic partners, regulatory clearance, manufacturing scale-up and reimbursement; no product-sales revenue had been recorded.
Company facts
No analyst consensus on record.
Not reported.
Not reported.
No dividends on record.
| Insiders1 holder · as of Feb 17, 2026 | 18.98% | 1.33M shares | |
| Otherremainder | 81.02% | 5.69M shares |
7.02M company shares as of Aug 21, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Dr. Ehud GellerInsider | 18.98% | 1.33M | 13Gfiled Feb 17, 2026 ↗ |
13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
Nothing filed in the last 12 months.
- Vericel
MACI is the principal U.S. autologous cartilage-repair alternative.
- Smith & Nephew (ADR)
Agili-C is an established off-the-shelf knee cartilage implant.
- Anika Therapeutics
Hyalofast targets single-stage repair of knee cartilage defects.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Regentis Biomaterials | $1.99 | −1.49% | $14.2M | — | — | — | — |
| Vericel | $41.50 | +1.42% | $2.09B | 87.4 | 61.6 | 6.8 | +22.5% |
| Smith & Nephew (ADR) | $28.58 | −0.34% | $12.04B | 19.0 | — | 1.9 | +3.7% |
| Anika Therapeutics | $21.58 | +2.23% | $288.4M | — | 35.1 | 2.4 | +15.6% |
| Median | 53.2 | 48.3 | 2.4 | +15.6% |